To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.

NCT02713243 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Bile Acid Diarrhea

Interventions

DRUG: LJN452
DRUG: Placebo to LJN452

Sponsor

Novartis Pharmaceuticals